Skip to main content

ABERCROMBIE & FITCH CO /DE/

For the period ended Feb 1, 2025. Filed Mar 31, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 31, 2025

ANF$152.81+2.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

FAIR VALUE

  1. FAIR VALUE

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The inputs used to measure fair value are prioritized based on a three-level hierarchy. The three levels of inputs to measure fair value are as follows:

Level 1—inputs are unadjusted quoted prices for identical assets or liabilities that are available in active markets that the Company can access at the measurement date.

Level 2—inputs are other than quoted market prices included within Level 1 that are observable for assets or liabilities, directly or indirectly.

Level 3—inputs to the valuation methodology are unobservable.

The lowest level of significant input determines the placement of the entire fair value measurement in the hierarchy.

The three levels of the hierarchy and the distribution of the Company’s assets and liabilities that are measured at fair value on a recurring basis, were as follows:

Assets and Liabilities at Fair Value as of February 1, 2025
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash equivalents (1)$304,072$1,013$—$305,085
Derivative instruments (2)—4,315—4,315
Rabbi Trust assets (3)1,16453,921—55,085
Restricted cash equivalents (1)3,0701,496—4,566
Total assets$308,306$60,745$—$369,051
Assets and Liabilities at Fair Value as of February 3, 2024
(in thousands)Level 1Level 2Level 3Total
Assets:
Cash equivalents (1)$349,174$26,975$—$376,149
Derivative instruments (2)—1,092—1,092
Rabbi Trust assets (3)1,16452,521—53,685
Restricted cash equivalents (1)4,2821,420—5,702
Total assets$354,620$82,008$—$436,628
Liabilities:
Derivative instruments (2)$—$539$—$539
Total liabilities$—$539$—$539

(1)Level 1 assets consisted of investments in money market funds and U.S. treasury bills. Level 2 assets consisted of time deposits with original maturities of less than three months.

(2)Level 2 assets and liabilities consisted primarily of foreign currency exchange forward contracts.

(3)Level 1 assets consisted of investments in money market funds. Level 2 assets consisted of trust-owned life insurance policies.

The Company’s Level 2 assets and liabilities consisted of:

Trust-owned life insurance policies, which were valued using the cash surrender value of the life insurance policies;

Time deposits with original maturities of three months or less, which were valued at cost, approximating fair value, due to the short-term nature of these investments and;

Derivative instruments, primarily foreign currency exchange forward contracts, which were valued using quoted market prices of the same or similar instruments, adjusted for counterparty risk.

The Company also holds certain investments that are not measured at fair value on a recurring basis on the Consolidated Balance Sheets, including held-to-maturity securities. Held-to-maturity securities consist primarily of time deposits with maturities less than one year, which are valued at amortized cost, approximating fair value.

Fair Value of Long-term Borrowings

The Company’s borrowings were carried at historical cost in the accompanying Condensed Consolidated Balance Sheet as of February 3, 2024. On July 15, 2024 (the “Redemption Date”), Abercrombie & Fitch Management Co. (“A&F Management”) redeemed all of its outstanding senior secured notes at par value, which had a fixed 8.75% interest rate and were scheduled to mature on July 15, 2025 (the “Senior Secured Notes”). As of the Redemption Date, the Senior Secured Notes wereno longer deemed outstanding.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.